Economic costs of failure to monitor adverse effects of second-generation antipsychotics: An underestimated factor

Psychiatric Services

Volumn 63, Issue 3, 2012, Pages 202-204

  Jerrell, Jeanette M ^a   McIntyre, Roger S ^b   Black, George B ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADVERSE OUTCOME; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MEDICAID; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; PATIENT MONITORING; PRESCRIPTION; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN; ADOLESCENT; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG MONITORING; ECONOMICS; HEALTH CARE COST; HEALTH CARE SURVEY; MASS SCREENING; MENTAL DISEASE; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; QUALITATIVE RESEARCH; RISK FACTOR; STANDARD; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CHILD; DRUG MONITORING; GLUCOSE METABOLISM DISORDERS; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HUMANS; MASS SCREENING; MENTAL DISORDERS; MENTAL HEALTH SERVICES; QUALITATIVE RESEARCH; RISK FACTORS; UNITED STATES;

EID: 84858210179     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.20120p202     Document Type: Short Survey

References (10)

1. DeHert M, Correll CU, Bobes J, et al: Physical illness in patients with severe mental disorders: I. Prevalence, impact of medications, and disparities in health care. World Psychiatry 10:52-77, 2011
2. Fleischhacker WW, Cetkovich-Bakmas M, DeHert M, et al: Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry 69:514-519, 2008 (Pubitemid 351792324)
3. Rummel-Kluge C, Komossa K, Schwarz S, et al: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123:225-233, 2010
4. FDA to require diabetes warning on antipsychotics. Psychiatric News 38(20):1,27, 2003
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
6. Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline-concordant monitoring of metabolic risk in people with antipsychotic medication: systematic review and metaanalysis of screening practices. Psychological Medicine 42:125-147, 2011
7. Leslie DL, Rosenheck RA: Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes. Psychiatric Services 56:803-809, 2005 (Pubitemid 40967456)
8. Jerrell JM, McIntyre RS: Health care service use and cost among pediatric clients developing adverse events during treatment with antipsychotics. Value in Health 12: 716-722, 2009
9. Jerrell JM, McIntyre RS, Tripathi A: Incidence and costs of metabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clinical Schizophrenia and Related Psychoses 4:161-168, 2010
10. Newcomer JW, Hennekens CH: Severe mental illness and risk of cardiovascular disease. JAMA 298:1794-1796, 2007 (Pubitemid 47598448)